Cerus (CERS)
(Delayed Data from NSDQ)
$1.57 USD
-0.15 (-8.72%)
Updated Oct 31, 2024 03:59 PM ET
After-Market: $1.56 -0.01 (-0.64%) 7:24 PM ET
3-Hold of 5 3
C Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.57 USD
-0.15 (-8.72%)
Updated Oct 31, 2024 03:59 PM ET
After-Market: $1.56 -0.01 (-0.64%) 7:24 PM ET
3-Hold of 5 3
C Value B Growth D Momentum B VGM
Zacks News
Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of 30.00% and 14.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cerus (CERS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of 10.00% and 20.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Cerus (CERS) Q2 Earnings Expected to Decline
by Zacks Equity Research
Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of -11.11% and 8.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Cerus (CERS) Is Up 2.47% in One Week: What You Should Know
by Zacks Equity Research
Does Cerus (CERS) have what it takes to be a top stock pick for momentum investors? Let's find out.
All You Need to Know About Cerus (CERS) Rating Upgrade to Buy
by Zacks Equity Research
Cerus (CERS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of 33.33% and 2.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Cerus (CERS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: TTOO, KMDA and CERS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: TTOO, KMDA and CERS
3 Plasma Stocks to Win Big on FDA's Convalescent EUA
by Tirthankar Chakraborty
Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -
Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of 10.00% and 0.01%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Cerus (CERS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Cerus (CERS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (CERS) Outperforming Other Medical Stocks This Year?
Cerus (CERS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Cerus (CERS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of 0.00% and 5.74%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Moving Average Crossover Alert: Cerus
by Zacks Equity Research
Cerus Corporation (CERS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Will Cerus (CERS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cerus Corporation (CERS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cerus Corporation (CERS).
Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of -18.18% and 2.76%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Cerus (CERS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of -8.33% and 5.50%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cerus (CERS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of -16.67% and 11.42%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cerus (CERS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.